Literature DB >> 27010618

Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.

Sophie A Aschenbroich1, Eric R Lafontaine2, Robert J Hogan2,3.   

Abstract

Burkholderia pseudomallei and Burkholderia mallei are pathogenic bacteria causing fatal infections in animals and humans. Both organisms are classified as Tier 1 Select Agents owing to their highly fatal nature, potential/prior use as bioweapons, severity of disease via respiratory exposure, intrinsic resistance to antibiotics, and lack of a current vaccine. Disease manifestations range from acute septicemia to chronic infection, wherein the facultative intracellular lifestyle of these organisms promotes persistence within a broad range of hosts. This ability to thrive intracellularly is thought to be related to exploitation of host immune response signaling pathways. There are currently considerable gaps in our understanding of the molecular strategies employed by these pathogens to modulate these pathways and evade intracellular killing. A better understanding of the specific molecular basis for dysregulation of host immune responses by these organisms will provide a stronger platform to identify novel vaccine targets and develop effective countermeasures.

Entities:  

Keywords:  Burkholderia; CpG; Toll-like receptor; adjuvant; cytokine; downregulation; immunomodulation; innate immunity; negative regulators; siRNA

Mesh:

Substances:

Year:  2016        PMID: 27010618     DOI: 10.1586/14760584.2016.1170598

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  15 in total

1.  DNA vaccination resurfaces in the struggle against melioidosis.

Authors:  Sophie A Aschenbroich
Journal:  Virulence       Date:  2017-06-02       Impact factor: 5.882

2.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

Review 3.  Emerging role of biologics for the treatment of melioidosis and glanders.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  Expert Opin Biol Ther       Date:  2019-10-15       Impact factor: 4.388

4.  Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  NPJ Vaccines       Date:  2020-09-10       Impact factor: 7.344

Review 5.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

Review 6.  Melioidosis.

Authors:  W Joost Wiersinga; Harjeet S Virk; Alfredo G Torres; Bart J Currie; Sharon J Peacock; David A B Dance; Direk Limmathurotsakul
Journal:  Nat Rev Dis Primers       Date:  2018-02-01       Impact factor: 52.329

7.  A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates.

Authors:  Sarah M Baker; Christopher J H Davitt; Natalya Motyka; Nicole L Kikendall; Kasi Russell-Lodrigue; Chad J Roy; Lisa A Morici
Journal:  Vaccines (Basel)       Date:  2017-12-09

Review 8.  Innate immune response to Burkholderia mallei.

Authors:  Kamal U Saikh; Tiffany M Mott
Journal:  Curr Opin Infect Dis       Date:  2017-06       Impact factor: 4.915

9.  Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application.

Authors:  Jacqueline M Lankelma; Alex Wagemakers; Emma Birnie; Bastiaan W Haak; Jos J A Trentelman; Tassili A F Weehuizen; Jasmin Ersöz; Joris J T H Roelofs; Joppe W Hovius; W Joost Wiersinga; Adriaan D Bins
Journal:  Virulence       Date:  2017-04-19       Impact factor: 5.882

10.  Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed TH1-TH17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Heather L Stevenson; Alfredo G Torres
Journal:  mBio       Date:  2021-06-29       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.